Newcastle Confidence in Concept 2016
Lead Research Organisation:
Newcastle University
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Organisations
Publications
Becker KA
(2018)
Sphingolipids as targets for inhalation treatment of cystic fibrosis.
in Advanced drug delivery reviews
Bojic S
(2018)
CD200 Expression Marks a Population of Quiescent Limbal Epithelial Stem Cells with Holoclone Forming Ability.
in Stem cells (Dayton, Ohio)
Chichagova V
(2018)
Cellular regeneration strategies for macular degeneration: past, present and future.
in Eye (London, England)
Da Conceicao Ribeiro R
(2018)
Reactive jet impingement bioprinting of high cell density gels for bone microtissue fabrication.
in Biofabrication
Delpiano L
(2018)
Esomeprazole Increases Airway Surface Liquid pH in Primary Cystic Fibrosis Epithelial Cells.
in Frontiers in pharmacology
Duncan CJA
(2019)
Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2.
in Science immunology
Gardner AI
(2021)
Interferon regulatory factor 8 regulates expression of acid ceramidase and infection susceptibility in cystic fibrosis.
in The Journal of biological chemistry
Hunt NC
(2018)
The Application of Biomaterials to Tissue Engineering Neural Retina and Retinal Pigment Epithelium.
in Advanced healthcare materials
Kamala O
(2021)
Homodimeric Minimal Factor H: In Vivo Tracking and Extended Dosing Studies in Factor H Deficient Mice.
in Frontiers in immunology
| Description | A diagnostic accuracy study of portable EEG to triage acute stroke |
| Amount | £221,623 (GBP) |
| Organisation | Forest Devices (USA) |
| Sector | Private |
| Country | United States |
| Start | |
| Description | AuToDeCRA 2 - Matching physiology to function: study autologous tolerogenic dendritic cell therapy focus on delivery route |
| Amount | £1,106,921 (GBP) |
| Funding ID | 21811 |
| Organisation | Versus Arthritis |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2018 |
| End | 07/2022 |
| Description | Confidence in Concept 2018 - New tools to image pulmonary embolism without exposure to ionising radiation |
| Amount | £68,878 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2020 |
| End | 02/2021 |
| Description | Development of novel type I interferon inhibitors |
| Amount | £10,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2021 |
| Description | EPSRC Impact Accelerator Award |
| Amount | £45,000 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Investigating the antimicrobial activity of sphingoid bases as a novel therapy against respiratory infection in children |
| Amount | £181,792 (GBP) |
| Funding ID | BH181815 |
| Organisation | Newcastle upon Tyne Hospitals NHS Charity |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2019 |
| End | 02/2021 |
| Description | Investigating the antimicrobial activity of sphingosine as a novel therapy against respiratory infection in children |
| Amount | £181,792 (GBP) |
| Organisation | Newcastle upon Tyne Hospitals NHS Charity |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Investigation of replapsed Burkitt lymphoma |
| Amount | £1,500 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Medimmune Grant |
| Amount | £20,000 (GBP) |
| Funding ID | 8300264934 |
| Organisation | AstraZeneca |
| Department | MedImmune |
| Sector | Private |
| Country | United Kingdom |
| Start | 04/2017 |
| End | 05/2022 |
| Description | Microglia in the type I interferon system: protective and pathogenic mechanisms |
| Amount | £412,853 (GBP) |
| Funding ID | 211153 |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2018 |
| End | 11/2021 |
| Description | PREMNEC: Preterm enteroids for determining the mechanism of necrotising enterocolitis |
| Amount | £161,574 (GBP) |
| Organisation | Marie Curie |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Personalised Therapies for all: Restoring airway function in CF using Alternative Chloride Channels |
| Amount | £750,000 (GBP) |
| Organisation | Cystic Fibrosis Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Precision medicine technologies: shaping the future - Point-of-care for stroke subtype diagnosis to enable rapid treatment |
| Amount | £939,000 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Process Control and Novel Materials for the Reactive Jet Impingement Process |
| Amount | £1,145,056 (GBP) |
| Funding ID | EP/V013092/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2021 |
| End | 09/2024 |
| Description | Purines for Rapid Identification of Stroke Mimics (PRISM) |
| Amount | £711,974 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Sir Henry Dale Fellowship |
| Amount | £995,985 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2020 |
| Description | The role of tumour-infiltrating macrophages, dendritic cells, and T- regulatory cells in Classical Hodgkin lymphoma |
| Amount | £9,261 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Type 1 interferon in Zika virus neuropathy |
| Amount | £10,000 (GBP) |
| Organisation | British Medical Association (BMA) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Understanding the Properdin Paradox using C3 D1115N (gain-of-function) knock-in mice |
| Amount | £569,241 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Wellcome Trust ISSF - The role of tumour-infiltrating macrophages, dendritic cells, and T- regulatory cells in Classical Hodgkin lymphoma |
| Amount | £9,261 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | i4i Innovative diagnostic test for early stage, high risk, melanoma AMLo |
| Amount | £927,143 (GBP) |
| Funding ID | II-LA-0417-20001 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2018 |
| End | 12/2020 |
| Title | MODIFIED COMPLEMENT PROTEINS AND USES THEREOF |
| Description | Certain embodiments of the present invention relate to regulation of the innate immune system and complement activation. In particular, but not exclusively certain embodiments relate to a complement regulator protein and pharmaceutical compositions thereof for use in the treatment of diseases associated with or mediated by the alternative complement pathway and methods of treating such diseases and other subject matter. |
| IP Reference | WO2018197873 |
| Protection | Patent application published |
| Year Protection Granted | 2018 |
| Licensed | No |
| Impact | It is hoped that this invention will make an impact in the field of kidney transplantation. |